Multivariable analysis
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| Overall survival | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 0.93 | 0.50-1.70 | .81 |
| Age ≥57 y | 1.70 | 1.16-2.51 | .01 |
| Platelets <150 × 109/L | 1.46 | 1.00-2.13 | .05 |
| Leukocytes ≥25 × 109/L | 1.95 | 1.28-3.00 | .001 |
| CALR/MPL-genotype absent | 1.95 | 1.11-3.43 | .02 |
| Mismatched unrelated donor | 2.25 | 1.51-3.35 | <.001 |
| KPS 90% to 100% | 0.60 | 0.41-0.88 | .01 |
| ASXL1 mutation | 2.15 | 1.00-4.60 | .05 |
| Relapse-free survival | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 1.03 | 0.60-1.77 | .92 |
| Age ≥57 y | 1.46 | 1.03-2.08 | .03 |
| Leukocytes ≥25 × 109/L | 1.50 | 1.00-2.23 | .05 |
| CALR/MPL-genotype absent | 2.41 | 1.46-3.97 | .001 |
| Mismatched unrelated donor | 1.92 | 1.35-2.73 | <.001 |
| ASXL1 mutation | 1.45 | 1.03-2.05 | .03 |
| Nonrelapse mortality | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 0.62 | 0.27-1.40 | .25 |
| Age ≥57 y | 1.60 | 1.05-2.45 | .03 |
| Leukocytes ≥25 × 109/L | 1.62 | 1.00-2.61 | .05 |
| CALR/MPL-genotype absent | 2.54 | 1.36-4.74 | .003 |
| Mismatched unrelated donor | 2.42 | 1.61-3.63 | <.001 |
| KPS 90% to 100% | 0.61 | 0.40-0.92 | .02 |
| Relapse | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 2.29 | 1.15-4.55 | .02 |
| CALR/MPL-genotype absent | 2.15 | 1.02-4.54 | .04 |
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| Overall survival | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 0.93 | 0.50-1.70 | .81 |
| Age ≥57 y | 1.70 | 1.16-2.51 | .01 |
| Platelets <150 × 109/L | 1.46 | 1.00-2.13 | .05 |
| Leukocytes ≥25 × 109/L | 1.95 | 1.28-3.00 | .001 |
| CALR/MPL-genotype absent | 1.95 | 1.11-3.43 | .02 |
| Mismatched unrelated donor | 2.25 | 1.51-3.35 | <.001 |
| KPS 90% to 100% | 0.60 | 0.41-0.88 | .01 |
| ASXL1 mutation | 2.15 | 1.00-4.60 | .05 |
| Relapse-free survival | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 1.03 | 0.60-1.77 | .92 |
| Age ≥57 y | 1.46 | 1.03-2.08 | .03 |
| Leukocytes ≥25 × 109/L | 1.50 | 1.00-2.23 | .05 |
| CALR/MPL-genotype absent | 2.41 | 1.46-3.97 | .001 |
| Mismatched unrelated donor | 1.92 | 1.35-2.73 | <.001 |
| ASXL1 mutation | 1.45 | 1.03-2.05 | .03 |
| Nonrelapse mortality | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 0.62 | 0.27-1.40 | .25 |
| Age ≥57 y | 1.60 | 1.05-2.45 | .03 |
| Leukocytes ≥25 × 109/L | 1.62 | 1.00-2.61 | .05 |
| CALR/MPL-genotype absent | 2.54 | 1.36-4.74 | .003 |
| Mismatched unrelated donor | 2.42 | 1.61-3.63 | <.001 |
| KPS 90% to 100% | 0.61 | 0.40-0.92 | .02 |
| Relapse | |||
| Blast group | |||
| Chronic-phase (reference) | |||
| Accelerated-phase | 2.29 | 1.15-4.55 | .02 |
| CALR/MPL-genotype absent | 2.15 | 1.02-4.54 | .04 |
HR, hazard ratio; KPS, Karnofsky performance score.